Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Cleveland Clinic

Sites in Cleveland, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1313
Shown on this page
12
Current sort
Recently updated
Campus scope
Cleveland Clinic, Cleveland, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Cleveland Clinic, Cleveland, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1069–1080 of 1,313 matching trials with a site at Cleveland Clinic, Cleveland, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

NCT03946527
Site status not listed — check the official record
View directory record Official record
Conditions
Paraganglioma, Pheochromocytoma
Interventions
Lanreotide
Drug
Lead sponsor
Antonio Fojo
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Recruiting No phase listed Observational

Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System

NCT06379321
Status at this site: Recruiting
View directory record Official record
Conditions
Knee Arthropathy, Recurrence, Knee Infection
Interventions
Triathlon Hinge Knee (THK) System
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Not listed
Enrollment
200 participants
Timeline
2024 – 2034
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Interventions
Naporafenib, Dacarbazine, Temozolomide, Trametinib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • San Francisco, California • Englewood, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Recruiting No phase listed Observational

Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry

NCT04536103
Status at this site: Recruiting
View directory record Official record
Conditions
Bone Diseases, Infectious, Musculoskeletal Diseases, Joint Diseases, Osteoarthritis, ACL Tear, Cartilage Degeneration
Interventions
MRI
Diagnostic Test
Lead sponsor
Xiaojuan Li
Other
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Not applicable Interventional

TRISCEND II Pivotal Trial

NCT04482062
Site status not listed — check the official record
View directory record Official record
Conditions
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
Interventions
Edwards EVOQUE System, Optimal Medical Therapy
Device · Drug
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
Status at this site: Recruiting
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Not applicable Interventional

Triathlon All-Polyethylene Tibia Outcomes Study

NCT04636190
Site status not listed — check the official record
View directory record Official record
Conditions
Arthropathy of Knee, Replacement, Knee Arthritis
Interventions
Triathlon All-Polyethylene Tibia Knee
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
6
States / cities
Lansing, Michigan • Buffalo, New York • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Recruiting Phase 3 Interventional

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

NCT06532006
Status at this site: Recruiting
View directory record Official record
Conditions
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
Interventions
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
29
States / cities
Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Recruiting Phase 2Phase 3 Interventional

Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy

NCT06721520
Status at this site: Recruiting
View directory record Official record
Conditions
Esophageal Cancer Surgery, Esophagectomy, Delayed Gastric Emptying Following Procedure, Esophageal Diseases, Esophageal Achalasia, Pylorus Dysfunction, Esophageal Dysmotility
Interventions
Botulinum Toxin A (Botox ), Pyloromyotomy
Biological · Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Phase 3 Interventional Results available

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT03414970
Site status not listed — check the official record
View directory record Official record
Conditions
Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions
Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy
Radiation · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
846
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Phase 2 Interventional Results available

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 6, 2026, 12:53 PM EST
Active, not recruiting Not applicable Interventional Results available

Cervical Spondylotic Myelopathy Surgical Trial

NCT02076113
Site status not listed — check the official record
View directory record Official record
Conditions
Cervical Spondylosis With Myelopathy
Interventions
Ventral (Front) decompression with Fusion, Dorsal (Back) Decompression with Fusion, Dorsal (back) Laminoplasty
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
45 Years to 80 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
15
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 6, 2026, 12:53 PM EST

About this Cleveland Clinic institution page

What this page lists
ClinicalTrials.gov records that list Cleveland Clinic in Cleveland, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.